FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Smith & Nephew plc Stock AnalysisComprehensive stock analysis for Smith & Nephew plc (SNN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSNN
SNN
Smith & Nephew plc
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
SNN
Home🔹Stocks🔹Smith & Nephew plc

Smith & Nephew plc

🇺🇸SNN•NYSE

Smith & Nephew plc

🇺🇸SNN•NYSE
Market cap
$11.55B
Sentiment

Your view on SNN

Mkt Cap
$11.55B
Sentiment
Your view
SNN
Smith & Nephew plc
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
SNN
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Smith & Nephew plc

Industry
Medical - Devices
Sector
Healthcare
CEO
Deepak S. Nath
Headquarters
Building 5, Watford, GB
Industry
Medical - Devices
Sector
Healthcare
CEO
Deepak S. Nath
Headquarters
Building 5, Watford, GB
Description

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide.

The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures.

It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems.

In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions.

Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems.

It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Smith & Nephew plc, and the rating behind it. SNN last traded at $27.50, 17.9× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Smith & Nephew plc. Starting points for Smith & Nephew plc: P/E 17.9, EPS $1.51, beta 0.69 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Smith & Nephew plc. Smith & Nephew plc paid $0.78 per share over the last year — a 2.8% yield at the current $27.50 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Smith & Nephew plc. Trailing twelve-month EPS for Smith & Nephew plc stands at $1.51. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Smith & Nephew plc. Smith & Nephew plc has reported as a listed company since 1999. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Smith & Nephew plc valued side by side against its closest peers. Smith & Nephew plc is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Smith & Nephew plc, and how their positions are changing. At a $11.55B market value, institutional positions materially move Smith & Nephew plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Smith & Nephew plc executives and directors. Shares of Smith & Nephew plc have traded between $23.69 and $38.79 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Smith & Nephew plc. Smith & Nephew plc is a $11.55B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Smith & Nephew plc. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Smith & Nephew plc. Coverage tracks Smith & Nephew plc within Medical - Devices (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • CNC — Centene Corporation
  • COO — The Cooper Companies, Inc.
  • FMS — Fresenius Medical Care AG & Co. KGaA
  • MEDP — Medpace Holdings, Inc.
  • NBIX — Neurocrine Biosciences, Inc.
  • RPRX — Royalty Pharma plc
  • TEM — Tempus AI, Inc.

More Medical - Devices companies

  • AVHHL — AVITA Medical, Inc.
  • AVR — Anteris Technologies Global Corp.
  • AVR.AX — Anteris Technologies Ltd
  • AXGN — AxoGen, Inc.
  • BBNX — Beta Bionics, Inc.
  • BCCOY — BICO Group AB (publ)
  • BDMD — Baird Medical Investment Holdings Limited
  • BFLY — Butterfly Network, Inc.
  • BIIO — Bionovate Technologies Corp
  • BIO — Bio-Rad Laboratories, Inc.
  • BIO-B — Bio-Rad Laboratories, Inc.
  • BJDX — Bluejay Diagnostics, Inc.

ETFs holding Smith & Nephew plc

  • DTEC — ALPS Disruptive Technologies ETF (0.93%)
  • ALRG — Allspring Exchange-Traded Funds Trust - Allspring LT Large Core ETF (0.58%)
  • KOMP — State Street SPDR S&P Kensho New Economies Composite ETF (0.08%)
  • AVSD — Avantis Responsible International Equity ETF (0.07%)
  • SPWO — SP Funds S&P World (ex-US) ETF (0.06%)
  • DFIC — Dimensional - International Core Equity 2 ETF (0.05%)
  • AVDE — Avantis International Equity ETF (0.04%)

News

Latest Market News